Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $122,606.13 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 6,667 shares of the business’s stock in a transaction on Wednesday, May 7th. The shares were sold at an average price of $18.39, for a total value of $122,606.13. Following the transaction, the chief operating officer now owns 309,976 shares of the company’s stock, valued at approximately $5,700,458.64. The trade was a 2.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Anish Patel also recently made the following trade(s):

• On Monday, April 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.04, for a total value of $120,272.68.
• On Friday, March 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.44, for a total transaction of $142,940.48.

Enliven Therapeutics Stock Down 0.6%

Shares of NASDAQ:ELVN opened at $18.51 on Monday. Enliven Therapeutics, Inc. has a 52-week low of $13.30 and a 52-week high of $30.03. The stock has a market cap of $908.21 million, a P/E ratio of -9.74 and a beta of 1.07. The business’s 50 day moving average is $19.06 and its 200 day moving average is $21.99.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.07. The firm had revenue of $0.03 million during the quarter. On average, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright raised their price target on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, March 21st.

Institutional Trading of Enliven Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ELVN. Invesco Ltd. grew its holdings in Enliven Therapeutics by 3.5% during the 4th quarter. Invesco Ltd. now owns 15,072 shares of the company’s stock worth $339,000 after acquiring an additional 508 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Enliven Therapeutics by 3.7% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company’s stock worth $451,000 after purchasing an additional 718 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after purchasing an additional 1,114 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Enliven Therapeutics by 14.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company’s stock valued at $233,000 after purchasing an additional 1,275 shares in the last quarter. Finally, MetLife Investment Management LLC increased its holdings in Enliven Therapeutics by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 21,746 shares of the company’s stock valued at $489,000 after buying an additional 1,285 shares during the period. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.